Adoptive cell therapy for Melanoma using tumour infiltrating lymphocytes: John Bridgeman

2 Views
administrator
administrator
07/30/23

A look at the use of TIL in Melanoma and future TIL engineering strategies. John Bridgeman is the Director of Cell Therapy Research at Immetacyte Ltd

Show more

0 Comments Sort By

No comments found

Facebook Comments

Up next